Ducentis – BioExpert Network

DUCENTIS

Therapies for inflammation and autoimmune disease

OWNER

Sector

Drug discovery

Stage

Pre-clinical

Funding needed

£200 000

Country

UK

CD200 transmits a de-activating signal which attenuates inflammatory responses

CD200 mutant has 15X greater affinity and 50X greater efficacy than wild-type

Potential therapeutic targets include transplant rejection and autoimmune and inflammatory diseases

If you want to have more information or you want to review the project, you have to login or register

Contact the entrepreneur

Share your thoughts with other BioExperts

KEEP REVIEWING

Funding: 5.000.000$
Stage: Development, market readiness, clinical trial
Sector: Biotech
+

BioZen Limited

BioZen Limited Developing the world's first approved medica...
Funding: 500.000€
Stage: Development, market readiness, clinical trial
Sector: Medical Device
+

Laboratorios Isimo, SL

Laboratorios Isimo, SL Laboratorios Isimo, SL Medical Devic...

©2023 BioExpert Network

About cookies

This website uses cookies to give you the best user experience. If you continue browsing you are giving your consent for the acceptance of those cookies and the acceptance of our cookies policy.

If you continue to browse and use this website you are agreeing to comply with and be bound by the following Terms of Use

Aviso de cookies